These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14634710)

  • 1. The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
    Parrott AC; Rodgers J; Buchanan T; Scholey AB; Heffernan T; Ling J
    Psychopharmacology (Berl); 2004 Jan; 171(2):231-3. PubMed ID: 14634710
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
    Sumnall HR; Jerome L; Doblin R; Mithoefer MC
    Psychopharmacology (Berl); 2004 Jan; 171(2):229-30. PubMed ID: 14634709
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 4. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
    Daumann J; Hensen G; Thimm B; Rezk M; Till B; Gouzoulis-Mayfrank E
    Psychopharmacology (Berl); 2004 May; 173(3-4):398-404. PubMed ID: 14722704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users.
    Dafters RI; Hoshi R; Talbot AC
    Psychopharmacology (Berl); 2004 May; 173(3-4):405-10. PubMed ID: 12955295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More about parkinsonism after taking ecstasy.
    Sewell RA; Cozzi NV
    N Engl J Med; 1999 Oct; 341(18):1400; author reply 1401. PubMed ID: 10577096
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
    Kish SJ
    Mov Disord; 2003 Nov; 18(11):1219-23. PubMed ID: 14639660
    [No Abstract]   [Full Text] [Related]  

  • 8. Ecstasy (MDMA) and memory function: a meta-analytic update.
    Laws KR; Kokkalis J
    Hum Psychopharmacol; 2007 Aug; 22(6):381-8. PubMed ID: 17621368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press.
    Green AR
    Psychopharmacology (Berl); 2004 May; 173(3-4):231-3. PubMed ID: 14985917
    [No Abstract]   [Full Text] [Related]  

  • 10. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 11. Modelling the adverse effects associated with ecstasy use.
    Fisk JE; Murphy PN; Montgomery C; Hadjiefthyvoulou F
    Addiction; 2011 Apr; 106(4):798-805. PubMed ID: 21182557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDMA ("ecstasy") and neurotoxicity.
    Mithoefer M; Jerome L; Doblin R
    Science; 2003 Jun; 300(5625):1504-5; author reply 1504-5. PubMed ID: 12791964
    [No Abstract]   [Full Text] [Related]  

  • 13. What's in a Name? Correlates of Ecstasy Users Knowing or Agreeing that Molly is Ecstasy/MDMA.
    Palamar JJ
    J Psychoactive Drugs; 2018; 50(1):88-93. PubMed ID: 28937933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective neurocognitive deficits associated with multiple doses of ecstasy/MDMA: a reply to Cole.
    Fox HC; Parrott AC
    J Psychopharmacol; 2003 Jun; 17(2):242-4. PubMed ID: 12870575
    [No Abstract]   [Full Text] [Related]  

  • 15. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.
    Green AR; O'shea E; Colado MI
    Eur J Pharmacol; 2004 Oct; 500(1-3):3-13. PubMed ID: 15464016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety.
    Brookhuis KA; de Waard D; Samyn N
    Psychopharmacology (Berl); 2004 May; 173(3-4):440-5. PubMed ID: 14714102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Uys JD; Niesink RJ
    Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDMA, cortisol, and heightened stress in recreational ecstasy users.
    Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
    Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence.
    Dafters RI; Duffy F; O'Donnell PJ; Bouquet C
    Psychopharmacology (Berl); 1999 Jul; 145(1):82-90. PubMed ID: 10445376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.